T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future strategic roadmap. Its subsidiaries, Immunwork and T-E Meds, currently have five drug candidates at critical stages of development. Among them, two candidates are expected to advance into Phase II or Phase IIb clinical trials, with […]
Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard University, and the Massachusetts Institute of Technology (MIT), and went on to lead the development of Xolair, the world’s first anti-IgE drug—marking a groundbreaking milestone in the treatment of allergies and asthma. After achieving remarkable
Great news! Our latest publication presents TE-1146 as a novel therapeutic strategy for the treatment of multiple myeloma. We are thrilled to announce the publication of our paper, entitled “TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity,” in the prestigious journal Haematologica. This study represents a collaborative effort between T-E Meds and
Our Latest Research Published in Haematologica Read More »
